Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
Molecular Therapy Methods & Clinical Development · 2025-06 · 33 (2) · 101486
DOI: 10.1016/j.omtm.2025.101486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-06. Verfasst von Qi Guo und 7 weiteren Autor:innen. Beteiligte Einrichtung: UCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Hematopoietic stem/progenitor cell (HSPC)-based anti-HIV-1 gene therapy holds promise to provide life-long remission following a single treatment. Here we report a multi-pronged anti-HIV-1 HSPC-based gene therapy designed to defend against and attack HIV-1 infection. We developed a lentiviral vector capable of co-expressing three anti-HIV-1 genes. Two are designed to prevent infection, including a short hairpin RNA (shRNA) (CCR5sh1005) to knock down HIV-1 co-receptor CCR5 and a membrane-anchored HIV-1 fusion inhibitor (C46). The third gene is a CD4-based chimeric antigen receptor (CAR) designed to attack HIV-1-infected cells. Our vector also includes a non-signaling truncated human epidermal growth factor receptor (huEGFRt) which acts as a negative selection-based safety kill switch against transduced cells. Anti-HIV-1 vector-transduced human CD34+ HSPC efficiently reconstituted multi-lineage human hematopoietic cells in humanized bone marrow/liver/thymus (huBLT) mice. HIV-1 viral load was significantly reduced (1-log fold reduction, p 4-fold reduction, p < 0.01) in huBLT mice. These results demonstrate that our strategy is highly effective for HIV-1 inhibition, and that CTX-mediated negative selection can deplete anti-HIV-1 vector-modified cells in the event of unwanted adverse effects in huBLT mice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- UCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
- UCLA School of Nursing, UCLA, Los Angeles, CA 90095, USA.
- Shanghai Key Laboratory of Tumor System Regulation and Clinical Translation, Jiading Branch, Renji Hospital, Shanghai Cancer Institute, Shanghai 201800, China.
- Department of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.
- Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand.
- David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Förderung
- NIAID NIH HHS
Zitieren
APA
Guo, Q., Parikh, K., Zhang, J., Brinkley, A., Chen, G., Jakramonpreeya, N., Zhen, A., & An, D. S. (2025). Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Molecular Therapy Methods & Clinical Development, 33(2), 101486. https://doi.org/10.1016/j.omtm.2025.101486
Vancouver
Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, et al. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Molecular Therapy Methods & Clinical Development. 2025;33(2):101486. doi:10.1016/j.omtm.2025.101486
BibTeX
@article{Guo2025,
author = {Guo, Qi and Parikh, Keval and Zhang, Jian and Brinkley, Alexander and Chen, Grace and Jakramonpreeya, Natnicha and Zhen, Anjie and An, Dong Sung},
title = {Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
volume = {33},
number = {2},
pages = {101486},
doi = {10.1016/j.omtm.2025.101486}
}
EUVIMED